# Questions From the Trial Record

> Research Peptide FAQ — Semaglutide, Tirzepatide, Tesamorelin — mypeptidesrx — Frequently asked questions about three Research Peptide Fundamentals compounds — semaglutide, tirzepatide, and tesamorelin — answered from the peer-reviewed literature, with citations.

**RESEARCH PEPTIDE FUNDAMENTALS / FAQ**

Direct, citation-anchored answers to the questions readers most often bring to these three peptides.

## What is semaglutide?

Semaglutide is a synthetic peptide that acts as a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, a hormone the gut releases after eating. It shares about 94% of its amino-acid sequence with native human GLP-1, modified to resist rapid breakdown and to bind albumin in the blood, which extends its working life to about a week. It is FDA-approved for type 2 diabetes, chronic weight management, cardiovascular-risk reduction, kidney-disease-event reduction, and (since 2025) a liver condition called MASH [2][3][4]. It is a prescription medicine, available as a once-weekly injection or a once-daily fasted oral tablet — not a research-only or over-the-counter compound.

## What is semaglutide used for?

Clinically, semaglutide's FDA-approved uses are: lowering blood glucose in type 2 diabetes; reducing body weight in adults with obesity or overweight (at the higher 2.4 mg weekly dose); reducing major cardiovascular events in adults with established cardiovascular disease and overweight or obesity [3]; reducing kidney-disease events in type 2 diabetes with chronic kidney disease [2]; and treating MASH, a liver condition, since 2025. The STEP 1 trial is the basis for the weight-management approval specifically, showing a mean -14.9% body-weight change at 68 weeks versus -2.4% for placebo [4]. Each of these is a distinct, separately trialed indication — not a single blanket approval.

## How does semaglutide work?

Semaglutide activates GLP-1 receptors throughout the body. In the pancreas, it increases insulin release only when blood glucose is already elevated and suppresses glucagon release — a glucose-dependent mechanism that keeps hypoglycemia risk low when it is used alone. It slows gastric emptying, which blunts blood-sugar spikes after meals and is also the mechanistic root of the nausea some people report. In the brain, it reaches hypothalamic and brainstem circuits that regulate appetite and fullness, which is the basis of its weight effect. GLP-1 receptors in the heart and kidney appear to carry additional protective effects, which the SELECT and FLOW trials were designed specifically to test [2][3].

## How does semaglutide work for weight loss?

The weight-loss effect is primarily central, not digestive. Semaglutide reaches GLP-1 receptors in the hypothalamic arcuate nucleus and the brainstem area postrema, activating neurons associated with fullness (POMC/CART) and suppressing neurons associated with hunger (NPY/AgRP). Patients frequently describe this as a quieting of 'food noise' — reduced preoccupation with food and meal-planning — though that specific patient-reported language comes from anecdotal sources, not a controlled measurement (see the semaglutide page). Slowed gastric emptying adds a secondary, more mechanical fullness effect. In the pivotal STEP 1 trial, this combination produced a mean -14.9% body-weight reduction at 68 weeks versus -2.4% with placebo [4].

## What is tirzepatide?

Tirzepatide is a 39-amino-acid synthetic peptide that activates two receptors at once — GIP and GLP-1 — rather than one. It is sometimes called a 'twincretin.' It is FDA-approved for type 2 diabetes (2022), chronic weight management (2023), and moderate-to-severe obstructive sleep apnea in adults with obesity [6]. In the one direct head-to-head trial against semaglutide, tirzepatide produced significantly greater weight loss over 72 weeks (-20.2% vs -13.7%, P<0.001) [1]. It is a prescription medicine administered by once-weekly subcutaneous injection.

## How does tirzepatide work?

Tirzepatide's GLP-1 arm performs the same core job semaglutide's does — glucose-dependent insulin release, glucagon suppression, and slowed gastric emptying. Its GIP arm adds to that: GIP receptors in adipose tissue and the central nervous system are believed to contribute incremental appetite and metabolic effects, though the exact division of labor between the two receptors is not fully resolved even in the discovery literature [6]. In vitro assays show the two receptors are engaged asymmetrically, with GIPR activation stronger than GLP-1R activation — a biased-agonism profile that may partly explain tirzepatide's larger effect sizes relative to single-receptor GLP-1 drugs, though this remains an area of ongoing research rather than settled mechanism.

## What does tirzepatide do in the body?

In the pancreas, tirzepatide boosts glucose-dependent insulin release and suppresses glucagon, improving blood-sugar control with low hypoglycemia risk when used alone. In the gut, it slows gastric emptying, contributing to both prolonged fullness and the nausea some people report. In the brain, it acts on hypothalamic appetite circuits to reduce hunger. Body-composition data from its pivotal SURMOUNT-1 trial show that most, though not all, of the weight lost is fat mass rather than lean mass, a pattern broadly typical of significant weight loss by any method [8].

## What is tirzepatide used for?

Tirzepatide's FDA-approved uses are type 2 diabetes (since May 2022), chronic weight management in adults with obesity or overweight plus a weight-related condition (since November 2023), and moderate-to-severe obstructive sleep apnea in adults with obesity. In SURPASS-2, it outperformed semaglutide 1 mg on both HbA1c reduction and weight loss in type 2 diabetes over 40 weeks [9]. In SURMOUNT-5, it outperformed semaglutide's own maximum tolerated dose on weight loss in adults with obesity [1]. It is a prescription medicine, not available for self-administration outside medical supervision.

## What is tesamorelin?

Tesamorelin is a synthetic, 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH), modified at the N-terminus to resist rapid enzymatic breakdown. Unlike semaglutide and tirzepatide, it does not touch the GLP-1/GIP incretin system at all — it works one step upstream, on the pituitary gland. It was FDA-approved in 2010 for exactly one indication: reducing excess visceral fat in HIV-infected adults with antiretroviral-associated lipodystrophy [11][15]. It has no other FDA-approved use; it is given by subcutaneous injection.

## What does tesamorelin do?

Tesamorelin binds the GHRH receptor on pituitary cells and stimulates the body's own pulsatile release of growth hormone (GH), rather than supplying GH directly. That GH drives the liver to produce IGF-1, and together GH and IGF-1 promote fat breakdown with a documented preference for visceral (deep abdominal) fat. In its approved population, the pivotal trial found a 15.2% reduction in visceral adipose tissue over 26 weeks versus a 5.0% increase with placebo, alongside a 50 mg/dL drop in triglycerides and an 81% rise in IGF-1 [15]. Because it raises IGF-1, a growth factor, active malignancy is a labeled contraindication.

## How does tesamorelin work?

Tesamorelin binds the GHRH receptor on anterior-pituitary somatotroph cells, triggering a Gs-protein/cAMP signaling cascade that stimulates synthesis and release of growth hormone in the body's natural pulsatile rhythm, rather than flooding the system with a flat exogenous dose. The resulting GH drives hepatic IGF-1 production, and GH plus IGF-1 together promote lipolysis, preferentially in visceral fat. A small, short study in 13 healthy men found this raised overnight GH and IGF-1 significantly over two weeks without a measurable change in fasting glucose or insulin sensitivity — a reassuring but genuinely limited (n=13, 2-week) finding, not a large or long-run one [13].

## Will tesamorelin help me lose belly fat?

This is not a question this desk can answer for an individual, and no dose or plan is recommended here. What can be reported: in the population tesamorelin is actually approved for — adults with HIV-associated lipodystrophy — the pivotal trial found a 15.2% reduction in visceral (deep abdominal) fat over 26 weeks versus a 5.0% increase with placebo [15], and a 2026 meta-analysis pooling five trials in that same population found a mean visceral-fat reduction of 27.71 cm2 [10]. That evidence does not establish the same effect in people outside HIV-associated lipodystrophy, because that population is not what the pivotal trials studied. Fat also reaccumulated once the drug was stopped in the 52-week program, meaning any effect appears to require continued use [14]. Anyone considering tesamorelin for any reason should discuss it with a licensed clinician.

---

An independent research summary that reports evidence quality honestly, including where it's thin — not a clinic, not a pharmacy, not medical advice.